nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—PTGS2—muscle cancer	0.732	1	CbGaD
Tolmetin—PTGS2—Etoposide—muscle cancer	0.0813	0.429	CbGbCtD
Tolmetin—PTGS1—Etoposide—muscle cancer	0.0687	0.362	CbGbCtD
Tolmetin—SLC22A6—Methotrexate—muscle cancer	0.0398	0.21	CbGbCtD
Tolmetin—MPO—C-MYB transcription factor network—MYF6—muscle cancer	0.0027	0.0965	CbGpPWpGaD
Tolmetin—PTGS2—hindlimb—muscle cancer	0.00209	0.105	CbGeAlD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MYF5—muscle cancer	0.00208	0.0744	CbGpPWpGaD
Tolmetin—TDO2—head—muscle cancer	0.00206	0.104	CbGeAlD
Tolmetin—PTGS2—appendage—muscle cancer	0.00179	0.09	CbGeAlD
Tolmetin—CXCL8—smooth muscle tissue—muscle cancer	0.00176	0.0886	CbGeAlD
Tolmetin—Ketorolac—PTGS2—muscle cancer	0.00154	0.221	CrCbGaD
Tolmetin—Bromfenac—PTGS2—muscle cancer	0.00148	0.212	CrCbGaD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—muscle cancer	0.00134	0.0479	CbGpPWpGaD
Tolmetin—CXCL8—bone marrow—muscle cancer	0.00128	0.0645	CbGeAlD
Tolmetin—Lumiracoxib—PTGS2—muscle cancer	0.00126	0.18	CrCbGaD
Tolmetin—CXCL8—vagina—muscle cancer	0.00123	0.0618	CbGeAlD
Tolmetin—Fenbufen—PTGS2—muscle cancer	0.00114	0.164	CrCbGaD
Tolmetin—CXCL8—testis—muscle cancer	0.0011	0.0551	CbGeAlD
Tolmetin—MPO—C-MYB transcription factor network—CD34—muscle cancer	0.00107	0.0384	CbGpPWpGaD
Tolmetin—MPO—C-MYB transcription factor network—MYOD1—muscle cancer	0.00107	0.0384	CbGpPWpGaD
Tolmetin—TDO2—Tryptophan metabolism—MDM2—muscle cancer	0.000996	0.0357	CbGpPWpGaD
Tolmetin—MPO—renal system—muscle cancer	0.000993	0.0499	CbGeAlD
Tolmetin—Suprofen—PTGS2—muscle cancer	0.000953	0.136	CrCbGaD
Tolmetin—PTGS2—C-MYB transcription factor network—MYF6—muscle cancer	0.000876	0.0313	CbGpPWpGaD
Tolmetin—CXCL8—Overview of nanoparticle effects—PTGS2—muscle cancer	0.000759	0.0272	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MED12—muscle cancer	0.000757	0.0271	CbGpPWpGaD
Tolmetin—MPO—bone marrow—muscle cancer	0.000751	0.0377	CbGeAlD
Tolmetin—MPO—head—muscle cancer	0.000664	0.0334	CbGeAlD
Tolmetin—MPO—testis—muscle cancer	0.000642	0.0322	CbGeAlD
Tolmetin—Indomethacin—PTGS2—muscle cancer	0.000606	0.0868	CrCbGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—TP73—muscle cancer	0.000595	0.0213	CbGpPWpGaD
Tolmetin—PTGS2—embryo—muscle cancer	0.000595	0.0299	CbGeAlD
Tolmetin—CXCL8—Bladder Cancer—CDKN2A—muscle cancer	0.000549	0.0196	CbGpPWpGaD
Tolmetin—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—muscle cancer	0.000535	0.0191	CbGpPWpGaD
Tolmetin—CXCL8—Bladder Cancer—MDM2—muscle cancer	0.000532	0.0191	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—HMGA1—muscle cancer	0.000505	0.0181	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—TIMM10—muscle cancer	0.000493	0.0177	CbGpPWpGaD
Tolmetin—PTGS1—smooth muscle tissue—muscle cancer	0.000489	0.0246	CbGeAlD
Tolmetin—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.000489	0.0209	CcSEcCtD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—muscle cancer	0.000476	0.017	CbGpPWpGaD
Tolmetin—PTGS1—renal system—muscle cancer	0.000471	0.0237	CbGeAlD
Tolmetin—PTGS2—smooth muscle tissue—muscle cancer	0.000468	0.0235	CbGeAlD
Tolmetin—PTGS2—renal system—muscle cancer	0.00045	0.0226	CbGeAlD
Tolmetin—Cardiac failure congestive—Etoposide—muscle cancer	0.000434	0.0185	CcSEcCtD
Tolmetin—PTGS1—cardiac atrium—muscle cancer	0.000422	0.0212	CbGeAlD
Tolmetin—PTGS1—Overview of nanoparticle effects—PTGS2—muscle cancer	0.000419	0.015	CbGpPWpGaD
Tolmetin—MPO—C-MYB transcription factor network—KIT—muscle cancer	0.000411	0.0147	CbGpPWpGaD
Tolmetin—Stomatitis—Dactinomycin—muscle cancer	0.000408	0.0174	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Etoposide—muscle cancer	0.000406	0.0173	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—VEGFA—muscle cancer	0.000404	0.0145	CbGpPWpGaD
Tolmetin—Dysuria—Vincristine—muscle cancer	0.000392	0.0168	CcSEcCtD
Tolmetin—Agranulocytosis—Dactinomycin—muscle cancer	0.000391	0.0167	CcSEcCtD
Tolmetin—Weight decreased—Vincristine—muscle cancer	0.00038	0.0162	CcSEcCtD
Tolmetin—Hepatitis—Dactinomycin—muscle cancer	0.000376	0.016	CcSEcCtD
Tolmetin—Proteinuria—Methotrexate—muscle cancer	0.000369	0.0158	CcSEcCtD
Tolmetin—PTGS1—tendon—muscle cancer	0.000368	0.0185	CbGeAlD
Tolmetin—Stomatitis—Vincristine—muscle cancer	0.000365	0.0156	CcSEcCtD
Tolmetin—Protein urine present—Methotrexate—muscle cancer	0.000364	0.0156	CcSEcCtD
Tolmetin—Erythema multiforme—Dactinomycin—muscle cancer	0.000355	0.0152	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.000354	0.0151	CcSEcCtD
Tolmetin—Glossitis—Methotrexate—muscle cancer	0.000352	0.015	CcSEcCtD
Tolmetin—PTGS2—tendon—muscle cancer	0.000351	0.0176	CbGeAlD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—muscle cancer	0.00035	0.0125	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—MYOD1—muscle cancer	0.000349	0.0125	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—CD34—muscle cancer	0.000349	0.0125	CbGpPWpGaD
Tolmetin—PTGS1—Eicosanoid Synthesis—PTGS2—muscle cancer	0.000348	0.0124	CbGpPWpGaD
Tolmetin—PTGS1—vagina—muscle cancer	0.000341	0.0171	CbGeAlD
Tolmetin—PTGS2—bone marrow—muscle cancer	0.00034	0.0171	CbGeAlD
Tolmetin—MPO—C-MYB transcription factor network—CDKN2A—muscle cancer	0.000333	0.0119	CbGpPWpGaD
Tolmetin—PTGS2—vagina—muscle cancer	0.000326	0.0164	CbGeAlD
Tolmetin—CXCL8—Cellular Senescence—HMGA1—muscle cancer	0.000319	0.0114	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—FH—muscle cancer	0.000319	0.0114	CbGpPWpGaD
Tolmetin—PTGS1—head—muscle cancer	0.000315	0.0158	CbGeAlD
Tolmetin—MPO—C-MYB transcription factor network—PTGS2—muscle cancer	0.000312	0.0112	CbGpPWpGaD
Tolmetin—CXCL8—Bladder Cancer—TP53—muscle cancer	0.000305	0.0109	CbGpPWpGaD
Tolmetin—Glossitis—Doxorubicin—muscle cancer	0.000305	0.013	CcSEcCtD
Tolmetin—PTGS1—testis—muscle cancer	0.000304	0.0153	CbGeAlD
Tolmetin—PTGS2—head—muscle cancer	0.000301	0.0151	CbGeAlD
Tolmetin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—muscle cancer	0.000301	0.0108	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—PTGS2—muscle cancer	0.0003	0.0107	CbGpPWpGaD
Tolmetin—Renal failure—Etoposide—muscle cancer	0.000298	0.0127	CcSEcCtD
Tolmetin—Stomatitis—Etoposide—muscle cancer	0.000295	0.0126	CcSEcCtD
Tolmetin—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000291	0.0104	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—CDKN2A—muscle cancer	0.000286	0.0102	CbGpPWpGaD
Tolmetin—Agranulocytosis—Etoposide—muscle cancer	0.000283	0.0121	CcSEcCtD
Tolmetin—Lymphadenopathy—Methotrexate—muscle cancer	0.000276	0.0118	CcSEcCtD
Tolmetin—Oedema—Dactinomycin—muscle cancer	0.000267	0.0114	CcSEcCtD
Tolmetin—Blood urea increased—Doxorubicin—muscle cancer	0.000265	0.0113	CcSEcCtD
Tolmetin—PTGS2—S1P1 pathway—VEGFA—muscle cancer	0.000262	0.00938	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Dactinomycin—muscle cancer	0.000261	0.0112	CcSEcCtD
Tolmetin—Erythema multiforme—Etoposide—muscle cancer	0.000257	0.011	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	0.000257	0.0092	CbGpPWpGaD
Tolmetin—Visual disturbance—Methotrexate—muscle cancer	0.000249	0.0106	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	0.000244	0.00875	CbGpPWpGaD
Tolmetin—Anaphylactoid reaction—Methotrexate—muscle cancer	0.000243	0.0104	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—HMGA1—muscle cancer	0.000241	0.00864	CbGpPWpGaD
Tolmetin—Lymphadenopathy—Doxorubicin—muscle cancer	0.000239	0.0102	CcSEcCtD
Tolmetin—Anaphylactic shock—Vincristine—muscle cancer	0.000239	0.0102	CcSEcCtD
Tolmetin—Oedema—Vincristine—muscle cancer	0.000239	0.0102	CcSEcCtD
Tolmetin—Thrombocytopenia—Vincristine—muscle cancer	0.000234	0.00997	CcSEcCtD
Tolmetin—CXCL8—G alpha (i) signalling events—CNR1—muscle cancer	0.000233	0.00835	CbGpPWpGaD
Tolmetin—Vascular purpura—Doxorubicin—muscle cancer	0.000228	0.00974	CcSEcCtD
Tolmetin—MPO—Folate Metabolism—TP53—muscle cancer	0.000225	0.00805	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Doxorubicin—muscle cancer	0.000225	0.0096	CcSEcCtD
Tolmetin—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000218	0.00932	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000212	0.00906	CcSEcCtD
Tolmetin—Purpura—Doxorubicin—muscle cancer	0.000212	0.00904	CcSEcCtD
Tolmetin—Abdominal pain—Dactinomycin—muscle cancer	0.000211	0.00901	CcSEcCtD
Tolmetin—Body temperature increased—Dactinomycin—muscle cancer	0.000211	0.00901	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.000211	0.009	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.000207	0.0074	CbGpPWpGaD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—muscle cancer	0.000207	0.0074	CbGpPWpGaD
Tolmetin—Constipation—Vincristine—muscle cancer	0.000204	0.00871	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000204	0.00871	CcSEcCtD
Tolmetin—Chest pain—Etoposide—muscle cancer	0.000202	0.00861	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.000201	0.00718	CbGpPWpGaD
Tolmetin—Abdominal discomfort—Methotrexate—muscle cancer	0.000195	0.00833	CcSEcCtD
Tolmetin—Gastrointestinal pain—Vincristine—muscle cancer	0.000195	0.00833	CcSEcCtD
Tolmetin—Anaphylactic shock—Etoposide—muscle cancer	0.000193	0.00825	CcSEcCtD
Tolmetin—PTGS1—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000193	0.00691	CbGpPWpGaD
Tolmetin—Asthenia—Dactinomycin—muscle cancer	0.000192	0.00818	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—VEGFA—muscle cancer	0.000191	0.00684	CbGpPWpGaD
Tolmetin—Dysuria—Methotrexate—muscle cancer	0.00019	0.00813	CcSEcCtD
Tolmetin—Thrombocytopenia—Etoposide—muscle cancer	0.000189	0.00808	CcSEcCtD
Tolmetin—Body temperature increased—Vincristine—muscle cancer	0.000189	0.00805	CcSEcCtD
Tolmetin—Abdominal pain—Vincristine—muscle cancer	0.000189	0.00805	CcSEcCtD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000185	0.00664	CbGpPWpGaD
Tolmetin—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000184	0.00784	CcSEcCtD
Tolmetin—Diarrhoea—Dactinomycin—muscle cancer	0.000183	0.0078	CcSEcCtD
Tolmetin—Drowsiness—Methotrexate—muscle cancer	0.000182	0.00775	CcSEcCtD
Tolmetin—Gastritis—Doxorubicin—muscle cancer	0.000181	0.00771	CcSEcCtD
Tolmetin—TDO2—Metabolism—MED12—muscle cancer	0.00018	0.00645	CbGpPWpGaD
Tolmetin—Renal failure—Methotrexate—muscle cancer	0.000178	0.00762	CcSEcCtD
Tolmetin—Stomatitis—Methotrexate—muscle cancer	0.000177	0.00755	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—PTGS2—muscle cancer	0.000176	0.0063	CbGpPWpGaD
Tolmetin—Haematuria—Methotrexate—muscle cancer	0.000173	0.00739	CcSEcCtD
Tolmetin—Somnolence—Etoposide—muscle cancer	0.000172	0.00734	CcSEcCtD
Tolmetin—Epistaxis—Methotrexate—muscle cancer	0.000171	0.00731	CcSEcCtD
Tolmetin—Asthenia—Vincristine—muscle cancer	0.000171	0.00731	CcSEcCtD
Tolmetin—Vomiting—Dactinomycin—muscle cancer	0.00017	0.00725	CcSEcCtD
Tolmetin—Agranulocytosis—Methotrexate—muscle cancer	0.000169	0.00723	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000168	0.00601	CbGpPWpGaD
Tolmetin—CXCL8—GPCR ligand binding—PTCH1—muscle cancer	0.000167	0.00599	CbGpPWpGaD
Tolmetin—Constipation—Etoposide—muscle cancer	0.000165	0.00706	CcSEcCtD
Tolmetin—Dysuria—Doxorubicin—muscle cancer	0.000165	0.00704	CcSEcCtD
Tolmetin—TDO2—Metabolism—ENO2—muscle cancer	0.000164	0.00588	CbGpPWpGaD
Tolmetin—Diarrhoea—Vincristine—muscle cancer	0.000163	0.00697	CcSEcCtD
Tolmetin—Hepatitis—Methotrexate—muscle cancer	0.000163	0.00696	CcSEcCtD
Tolmetin—Weight increased—Doxorubicin—muscle cancer	0.00016	0.00685	CcSEcCtD
Tolmetin—Weight decreased—Doxorubicin—muscle cancer	0.000159	0.00681	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—TP53—muscle cancer	0.000159	0.0057	CbGpPWpGaD
Tolmetin—Nausea—Dactinomycin—muscle cancer	0.000159	0.00677	CcSEcCtD
Tolmetin—Gastrointestinal pain—Etoposide—muscle cancer	0.000158	0.00675	CcSEcCtD
Tolmetin—Dizziness—Vincristine—muscle cancer	0.000158	0.00674	CcSEcCtD
Tolmetin—Drowsiness—Doxorubicin—muscle cancer	0.000157	0.00671	CcSEcCtD
Tolmetin—Visual impairment—Methotrexate—muscle cancer	0.000157	0.0067	CcSEcCtD
Tolmetin—Renal failure—Doxorubicin—muscle cancer	0.000155	0.0066	CcSEcCtD
Tolmetin—Erythema multiforme—Methotrexate—muscle cancer	0.000154	0.00658	CcSEcCtD
Tolmetin—Urticaria—Etoposide—muscle cancer	0.000154	0.00656	CcSEcCtD
Tolmetin—Stomatitis—Doxorubicin—muscle cancer	0.000153	0.00654	CcSEcCtD
Tolmetin—Body temperature increased—Etoposide—muscle cancer	0.000153	0.00652	CcSEcCtD
Tolmetin—Abdominal pain—Etoposide—muscle cancer	0.000153	0.00652	CcSEcCtD
Tolmetin—Urinary tract infection—Doxorubicin—muscle cancer	0.000153	0.00652	CcSEcCtD
Tolmetin—Tinnitus—Methotrexate—muscle cancer	0.000152	0.00649	CcSEcCtD
Tolmetin—Vomiting—Vincristine—muscle cancer	0.000152	0.00648	CcSEcCtD
Tolmetin—Haematuria—Doxorubicin—muscle cancer	0.00015	0.0064	CcSEcCtD
Tolmetin—Headache—Vincristine—muscle cancer	0.000149	0.00638	CcSEcCtD
Tolmetin—Epistaxis—Doxorubicin—muscle cancer	0.000148	0.00633	CcSEcCtD
Tolmetin—Agranulocytosis—Doxorubicin—muscle cancer	0.000147	0.00626	CcSEcCtD
Tolmetin—Nausea—Vincristine—muscle cancer	0.000142	0.00605	CcSEcCtD
Tolmetin—CXCL8—GPCR ligand binding—CNR1—muscle cancer	0.000141	0.00505	CbGpPWpGaD
Tolmetin—Hepatitis—Doxorubicin—muscle cancer	0.000141	0.00602	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—TP53—muscle cancer	0.00014	0.00502	CbGpPWpGaD
Tolmetin—Asthenia—Etoposide—muscle cancer	0.000139	0.00592	CcSEcCtD
Tolmetin—Visual impairment—Doxorubicin—muscle cancer	0.000136	0.00581	CcSEcCtD
Tolmetin—Erythema multiforme—Doxorubicin—muscle cancer	0.000133	0.0057	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—KIT—muscle cancer	0.000133	0.00477	CbGpPWpGaD
Tolmetin—Diarrhoea—Etoposide—muscle cancer	0.000132	0.00565	CcSEcCtD
Tolmetin—Tinnitus—Doxorubicin—muscle cancer	0.000132	0.00562	CcSEcCtD
Tolmetin—CXCL8—Cellular Senescence—CDKN2A—muscle cancer	0.000131	0.00468	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000129	0.00462	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KIDINS220—muscle cancer	0.000129	0.00461	CbGpPWpGaD
Tolmetin—Dizziness—Etoposide—muscle cancer	0.000128	0.00546	CcSEcCtD
Tolmetin—CXCL8—Cellular Senescence—MDM2—muscle cancer	0.000127	0.00454	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—PTGS2—muscle cancer	0.000123	0.0044	CbGpPWpGaD
Tolmetin—Vomiting—Etoposide—muscle cancer	0.000123	0.00525	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000123	0.0044	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000121	0.00435	CbGpPWpGaD
Tolmetin—Headache—Etoposide—muscle cancer	0.000121	0.00517	CcSEcCtD
Tolmetin—Flatulence—Doxorubicin—muscle cancer	0.000121	0.00517	CcSEcCtD
Tolmetin—Chest pain—Methotrexate—muscle cancer	0.000121	0.00516	CcSEcCtD
Tolmetin—Anaphylactic shock—Methotrexate—muscle cancer	0.000116	0.00494	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000115	0.00412	CbGpPWpGaD
Tolmetin—Nausea—Etoposide—muscle cancer	0.000115	0.0049	CcSEcCtD
Tolmetin—Thrombocytopenia—Methotrexate—muscle cancer	0.000113	0.00484	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000111	0.00397	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—CDKN2A—muscle cancer	0.000108	0.00388	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—TP53—muscle cancer	0.000105	0.00375	CbGpPWpGaD
Tolmetin—Chest pain—Doxorubicin—muscle cancer	0.000105	0.00446	CcSEcCtD
Tolmetin—Somnolence—Methotrexate—muscle cancer	0.000103	0.00439	CcSEcCtD
Tolmetin—Dyspepsia—Methotrexate—muscle cancer	0.000102	0.00435	CcSEcCtD
Tolmetin—Anaphylactic shock—Doxorubicin—muscle cancer	0.0001	0.00428	CcSEcCtD
Tolmetin—Oedema—Doxorubicin—muscle cancer	0.0001	0.00428	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—CDKN2A—muscle cancer	9.89e-05	0.00354	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Doxorubicin—muscle cancer	9.82e-05	0.00419	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—MDM2—muscle cancer	9.59e-05	0.00343	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Methotrexate—muscle cancer	9.47e-05	0.00404	CcSEcCtD
Tolmetin—Urticaria—Methotrexate—muscle cancer	9.2e-05	0.00393	CcSEcCtD
Tolmetin—Body temperature increased—Methotrexate—muscle cancer	9.15e-05	0.00391	CcSEcCtD
Tolmetin—Abdominal pain—Methotrexate—muscle cancer	9.15e-05	0.00391	CcSEcCtD
Tolmetin—Somnolence—Doxorubicin—muscle cancer	8.91e-05	0.00381	CcSEcCtD
Tolmetin—Dyspepsia—Doxorubicin—muscle cancer	8.82e-05	0.00377	CcSEcCtD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.69e-05	0.00311	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—PTCH1—muscle cancer	8.58e-05	0.00307	CbGpPWpGaD
Tolmetin—Constipation—Doxorubicin—muscle cancer	8.57e-05	0.00366	CcSEcCtD
Tolmetin—Asthenia—Methotrexate—muscle cancer	8.31e-05	0.00355	CcSEcCtD
Tolmetin—Gastrointestinal pain—Doxorubicin—muscle cancer	8.2e-05	0.0035	CcSEcCtD
Tolmetin—CXCL8—Metabolism of proteins—IGF2—muscle cancer	8.12e-05	0.00291	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—CNR1—muscle cancer	7.98e-05	0.00286	CbGpPWpGaD
Tolmetin—Urticaria—Doxorubicin—muscle cancer	7.96e-05	0.0034	CcSEcCtD
Tolmetin—Abdominal pain—Doxorubicin—muscle cancer	7.93e-05	0.00338	CcSEcCtD
Tolmetin—Body temperature increased—Doxorubicin—muscle cancer	7.93e-05	0.00338	CcSEcCtD
Tolmetin—Diarrhoea—Methotrexate—muscle cancer	7.92e-05	0.00338	CcSEcCtD
Tolmetin—Dizziness—Methotrexate—muscle cancer	7.66e-05	0.00327	CcSEcCtD
Tolmetin—Vomiting—Methotrexate—muscle cancer	7.36e-05	0.00314	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—VEGFA—muscle cancer	7.29e-05	0.00261	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—TP53—muscle cancer	7.28e-05	0.00261	CbGpPWpGaD
Tolmetin—Headache—Methotrexate—muscle cancer	7.25e-05	0.0031	CcSEcCtD
Tolmetin—CXCL8—Signaling by GPCR—CNR1—muscle cancer	7.25e-05	0.00259	CbGpPWpGaD
Tolmetin—Asthenia—Doxorubicin—muscle cancer	7.19e-05	0.00307	CcSEcCtD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	6.9e-05	0.00247	CbGpPWpGaD
Tolmetin—Nausea—Methotrexate—muscle cancer	6.88e-05	0.00294	CcSEcCtD
Tolmetin—Diarrhoea—Doxorubicin—muscle cancer	6.86e-05	0.00293	CcSEcCtD
Tolmetin—PTGS1—Metabolism—FH—muscle cancer	6.85e-05	0.00245	CbGpPWpGaD
Tolmetin—Dizziness—Doxorubicin—muscle cancer	6.63e-05	0.00283	CcSEcCtD
Tolmetin—Vomiting—Doxorubicin—muscle cancer	6.37e-05	0.00272	CcSEcCtD
Tolmetin—Headache—Doxorubicin—muscle cancer	6.28e-05	0.00268	CcSEcCtD
Tolmetin—Nausea—Doxorubicin—muscle cancer	5.95e-05	0.00254	CcSEcCtD
Tolmetin—TDO2—Metabolism—PTGS2—muscle cancer	5.72e-05	0.00205	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—TP53—muscle cancer	5.5e-05	0.00197	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.44e-05	0.00195	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—FH—muscle cancer	5.44e-05	0.00195	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PTCH1—muscle cancer	5.07e-05	0.00181	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TP53—muscle cancer	4.59e-05	0.00164	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—FOXO4—muscle cancer	4.36e-05	0.00156	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CNR1—muscle cancer	4.28e-05	0.00153	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.13e-05	0.00148	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—MED12—muscle cancer	3.87e-05	0.00139	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—ENO2—muscle cancer	3.53e-05	0.00126	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IGF2—muscle cancer	3.5e-05	0.00125	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ENO2—muscle cancer	3.35e-05	0.0012	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—FOXO1—muscle cancer	3.22e-05	0.00115	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.12e-05	0.00112	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—MED12—muscle cancer	3.07e-05	0.0011	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HMGA1—muscle cancer	3.04e-05	0.00109	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ENO2—muscle cancer	2.8e-05	0.001	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.76e-05	0.000988	CbGpPWpGaD
Tolmetin—PTGS2—Disease—FOXO4—muscle cancer	2.73e-05	0.000976	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KIT—muscle cancer	2.45e-05	0.000878	CbGpPWpGaD
Tolmetin—PTGS2—Disease—FOXO1—muscle cancer	2.01e-05	0.000721	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MDM2—muscle cancer	1.93e-05	0.000692	CbGpPWpGaD
Tolmetin—PTGS2—Disease—KIT—muscle cancer	1.54e-05	0.000549	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—VEGFA—muscle cancer	1.47e-05	0.000525	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PTGS2—muscle cancer	1.23e-05	0.00044	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MDM2—muscle cancer	1.21e-05	0.000433	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TP53—muscle cancer	1.11e-05	0.000397	CbGpPWpGaD
